Ashley Nicholls
YOU?
Author Swipe
View article: Predicting Personalised Therapeutic Combinations in Non-Small Cell Lung Cancer Using <i>In Silico</i> Modelling
Predicting Personalised Therapeutic Combinations in Non-Small Cell Lung Cancer Using <i>In Silico</i> Modelling Open
The disease burden from non-small cell lung cancer (NSCLC) adenocarcinoma is substantial, with around a million new cases diagnosed globally each year, and a 5-year survival rate of less than 20%. A lack of therapeutic options personalized…
View article: Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies
Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies Open
Tumour heterogeneity is thought to be a major barrier to successful cancer treatment due to the presence of drug resistant clonal lineages. However, identifying the characteristics of such lineages that underpin resistance to therapy has r…
View article: Author response: Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies
Author response: Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies Open
Article Figures and data Abstract Editor's evaluation eLife digest Introduction Results Discussion Materials and methods Data availability References Decision letter Author response Article and author information Metrics Abstract Tumour he…
View article: Creating a ‘Timeline’ of ductal carcinoma in situ to identify processes and biomarkers for progression towards invasive ductal carcinoma
Creating a ‘Timeline’ of ductal carcinoma in situ to identify processes and biomarkers for progression towards invasive ductal carcinoma Open
Ductal carcinoma in situ (DCIS) is considered a non-invasive precursor to breast cancer, and although associated with an increased risk of developing invasive disease, many women with DCIS will never progress beyond their in situ diagnosis…
View article: Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies
Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies Open
Tumor heterogeneity is thought to be a major barrier to successful cancer treatment due to the presence of drug resistant clonal lineages. However, identifying the characteristics of such lineages that underpin resistance to therapy has re…